Treatment of lupus nephritis

Sebastian Dolff; Jo H. M. Berden; Marc Bijl

doi:10.1586/ECI.10.79

Treatment of lupus nephritis

Sebastian Dolff^*, Jo H. M. Berden, Marc Bijl

^*Corresponding author for this work

Research output: Contribution to journal › Review article › peer-review

11 Citations (Scopus)

Abstract

Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns which has a crucial impact on the prognosis and treatment options for LN patients There are widely accepted therapeutic agents available such as cyclophosphamide mycophenolate mofetil azathioprine and corticosteroids Several trials have tried to determine a gold standard for induction and maintenance therapy in LN and the place of newer drugs biologicals has been investigated We review recently reported data on current treatment regimens in LN in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification

Original language	English
Pages (from-to)	901-911
Number of pages	11
Journal	Expert review of clinical immunology
Volume	6
Issue number	6
DOIs	https://doi.org/10.1586/ECI.10.79
Publication status	Published - Nov-2010

Keywords

glomerulonephritis
lupus nephritis
SLE
treatment
STEM-CELL TRANSPLANTATION
LONG-TERM PROGNOSIS
ANTI-DNA ANTIBODIES
MYCOPHENOLATE-MOFETIL
CONTROLLED-TRIAL
MEMBRANOUS NEPHROPATHY
INTRAVENOUS CYCLOPHOSPHAMIDE
RHEUMATOID-ARTHRITIS
MAINTENANCE THERAPY
DISEASE-ACTIVITY

Access to Document

10.1586/ECI.10.79

Handle.net

Persistent link

Cite this

@article{994105b942c1464abca7ab223a3e46bd,

title = "Treatment of lupus nephritis",

abstract = "Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns which has a crucial impact on the prognosis and treatment options for LN patients There are widely accepted therapeutic agents available such as cyclophosphamide mycophenolate mofetil azathioprine and corticosteroids Several trials have tried to determine a gold standard for induction and maintenance therapy in LN and the place of newer drugs biologicals has been investigated We review recently reported data on current treatment regimens in LN in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification",

keywords = "glomerulonephritis, lupus nephritis, SLE, treatment, STEM-CELL TRANSPLANTATION, LONG-TERM PROGNOSIS, ANTI-DNA ANTIBODIES, MYCOPHENOLATE-MOFETIL, CONTROLLED-TRIAL, MEMBRANOUS NEPHROPATHY, INTRAVENOUS CYCLOPHOSPHAMIDE, RHEUMATOID-ARTHRITIS, MAINTENANCE THERAPY, DISEASE-ACTIVITY",

author = "Sebastian Dolff and Berden, {Jo H. M.} and Marc Bijl",

year = "2010",

month = nov,

doi = "10.1586/ECI.10.79",

language = "English",

volume = "6",

pages = "901--911",

journal = "Expert review of clinical immunology",

issn = "1744-666X",

publisher = "Taylor & Francis Group",

number = "6",

}

TY - JOUR

T1 - Treatment of lupus nephritis

AU - Dolff, Sebastian

AU - Berden, Jo H. M.

AU - Bijl, Marc

PY - 2010/11

Y1 - 2010/11

N2 - Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns which has a crucial impact on the prognosis and treatment options for LN patients There are widely accepted therapeutic agents available such as cyclophosphamide mycophenolate mofetil azathioprine and corticosteroids Several trials have tried to determine a gold standard for induction and maintenance therapy in LN and the place of newer drugs biologicals has been investigated We review recently reported data on current treatment regimens in LN in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification

AB - Renal involvement in systemic lupus erythematosus patients is a severe disease manifestation characterized by various clinical and histopathological alterations The revised International Society of Nephrology/Renal Pathology Society 2003 classification defines the subclasses of lupus nephritis (LN) according to their pathological glomerular patterns which has a crucial impact on the prognosis and treatment options for LN patients There are widely accepted therapeutic agents available such as cyclophosphamide mycophenolate mofetil azathioprine and corticosteroids Several trials have tried to determine a gold standard for induction and maintenance therapy in LN and the place of newer drugs biologicals has been investigated We review recently reported data on current treatment regimens in LN in particular in the context of the International Society of Nephrology/Renal Pathology Society 2003 classification

KW - glomerulonephritis

KW - lupus nephritis

KW - SLE

KW - treatment

KW - STEM-CELL TRANSPLANTATION

KW - LONG-TERM PROGNOSIS

KW - ANTI-DNA ANTIBODIES

KW - MYCOPHENOLATE-MOFETIL

KW - CONTROLLED-TRIAL

KW - MEMBRANOUS NEPHROPATHY

KW - INTRAVENOUS CYCLOPHOSPHAMIDE

KW - RHEUMATOID-ARTHRITIS

KW - MAINTENANCE THERAPY

KW - DISEASE-ACTIVITY

U2 - 10.1586/ECI.10.79

DO - 10.1586/ECI.10.79

M3 - Review article

SN - 1744-666X

VL - 6

SP - 901

EP - 911

JO - Expert review of clinical immunology

JF - Expert review of clinical immunology

IS - 6

ER -

Treatment of lupus nephritis

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Cite this